NSE:FLUOROCHEM   GUJARAT FLUOROCHEM LTD
KEY POINTS
Product Portfolio: The company is the only PTFE / fluoropolymer manufacturer in India and a major supplier of fluoropolymers to Europe and USA. GFL holds domain expertise in four major product verticals: Fluoropolymers, Fluorospecialities, Refrigerants and Chemicals
1) Flouropolymers: Company is the leading producers of Fluoropolymers globally. It manufactures and markets a range of Fluoropolymers and Fluoro-elastomers eg PTFE, PFA, FEP, FKM, PVDF, Additives.
2) Fluorospeciality chemicals: In this segment, company offers products for the global agrochemical and pharmaceutical Industries eg Hf Based, Tfe Based, Kf Based.
3) Refrigerants: The company is the largest manufacturer of HCFC 22 in India and the preferred supplier for leading OEMs and service partners globally eg R22, R32, R407C, R410A.
4) Chemicals: The company is a leading producer of industrial chemicals such as Caustic Soda, Carbon Tetrachloride, Chlorine, Methylene Di Chloride, Hydrochloric Acid, Sodium Hydrogen Sulphate, Hydrogen Gas, Fluorspar, Anhydrous Hydrogen Chloride.

Also, GFL has developed technology and products which would help it to ride the wave of new and upcoming industrial verticals such as Electric Vehicles, Solar Panels, Hydrogen Fuel Cells /electrolyzers and Electrical batteries.

Manufacturing Units:
The company has two manufacturing complexes in Dahej for the Fluoropolymers and Chemicals, another one in Ranjitnagar for Fluorospecialities and last one in Morocco for Fluorspar Mining and Beneficiation.
The units work in the combined installed capacity of ~65,000 tons per annum (tpa) of HCFC, ~16,200 tpa of PTFE, ~134,750 tpa of caustic soda, and ~108,500 tpa of chloro-methane.
For Q2FY22, plants manufacturing Caustic Soda, Chloromethanes Fluoropolymer(PTFE) are running at full capacity and for the New Fluoropolymer; the capacity utilization is around ~65% which is expected to reach 100% utilization of existing capacity by Q4FY22. For speciality chemicals, Capacity utilization has been low for pharma related intermediates due to demand displacement in favor of Covid-19 related drugs. This is expected to start normalizing from Q4FY22

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.